{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:57:13Z","timestamp":1789016233326,"version":"build-2803163510"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-025-02552-w","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T01:28:14Z","timestamp":1751246894000},"page":"1573-1583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["New generation agents for glycemic control and diabetic retinopathy progression: what we need to know?"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6773-9967","authenticated-orcid":false,"given":"Stela","family":"Vujosevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1505-6029","authenticated-orcid":false,"given":"Caterina","family":"Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8518-5547","authenticated-orcid":false,"given":"Anna","family":"Ferrulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0267-3650","authenticated-orcid":false,"given":"Stefano","family":"De Cill\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4036-703X","authenticated-orcid":false,"given":"Paolo","family":"Nucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3183-0552","authenticated-orcid":false,"given":"Livio","family":"Luzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"2552_CR1","doi-asserted-by":"publisher","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","volume":"2","author":"TY Wong","year":"2016","unstructured":"Wong TY, Cheung CMG, Larsen M, Sharma S, Sim\u00f3 R (2016) Diabetic retinopathy. Nat Rev Dis Primers 2:16012. https:\/\/doi.org\/10.1038\/nrdp.2016.12","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 1","key":"2552_CR2","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.2337\/dc22-S012","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee (2022) Retinopathy, neuropathy, and foot care: standards of medical care in diabetes\u20142022. Diabetes Care 45(Suppl 1):S185\u2013S194. https:\/\/doi.org\/10.2337\/dc22-S012","journal-title":"Diabetes Care"},{"key":"2552_CR3","volume-title":"IDF diabetes atlas","author":"International Diabetes Federation","year":"2021","unstructured":"International Diabetes Federation (2021) IDF diabetes atlas, 10th edn. International Diabetes Federation, Brussels, Belgium","edition":"10"},{"issue":"3","key":"2552_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"JWY Yau","year":"2012","unstructured":"Yau JWY, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35(3):556\u2013564. https:\/\/doi.org\/10.2337\/dc11-1909Epub 2012 Feb 1","journal-title":"Diabetes Care"},{"issue":"9131","key":"2552_CR5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837\u2013853","journal-title":"Lancet"},{"issue":"7","key":"2552_CR6","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/archopht.116.7.874","volume":"116","author":"The Diabetes Control and Complications Trial (DCCT) Research Group","year":"1998","unstructured":"The Diabetes Control and Complications Trial (DCCT) Research Group (1998) Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol 116(7):874\u2013886. https:\/\/doi.org\/10.1001\/archopht.116.7.874","journal-title":"Arch Ophthalmol"},{"issue":"19","key":"2552_CR7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"8295","key":"2552_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/s0140-6736(82)90464-0","volume":"2","author":"JMM Hooymans","year":"1982","unstructured":"Hooymans JMM, Ballegooie EV, Schweitzer NM, Doorebos H, Reitsma WD, Slutter WJ (1982) Worsening of diabetic retinopathy with strict control of blood sugar. Lancet 2(8295):438. https:\/\/doi.org\/10.1016\/s0140-6736(82)90464-0","journal-title":"Lancet"},{"issue":"10","key":"2552_CR9","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s00125-009-1457-x","volume":"52","author":"JW Beulens","year":"2009","unstructured":"Beulens JW, Patel A, Vingerling JR, Cruickshank JK, Hughes AD, Stanton A et al (2009) Effects of blood pressure Lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia 52(10):2027\u20132036. https:\/\/doi.org\/10.1007\/s00125-009-1457-x","journal-title":"Diabetologia"},{"issue":"1","key":"2552_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13300-021-01190-z","volume":"13","author":"H Akil","year":"2022","unstructured":"Akil H, Burgess J, Nevitt S, Harding SP, Alam U, Burgess P (2022) Early worsening of retinopathy in type 1 and type 2 diabetes after rapid improvement in glycaemic control: a systematic review. Diabetes Ther 13(1):1\u201323. https:\/\/doi.org\/10.1007\/s13300-021-01190-z","journal-title":"Diabetes Ther"},{"issue":"12","key":"2552_CR11","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1172\/JCI17455","volume":"111","author":"T Kondo","year":"2003","unstructured":"Kondo T, Vicent D, Suzuma K, Yanagisawa M, King GL, Holzenberger M, Kahn CR (2003) Knockout of insulin and IGF-1 receptors on vascular endothelial cells protects against retinal neovascularization. J Clin Invest 111(12):1835\u20131842. https:\/\/doi.org\/10.1172\/JCI17455","journal-title":"J Clin Invest"},{"issue":"6471","key":"2552_CR12","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/bmj.290.6471.811","volume":"290","author":"K Dahl-J\u00f8rgensen","year":"1985","unstructured":"Dahl-J\u00f8rgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O (1985) Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed) 290(6471):811\u2013815. https:\/\/doi.org\/10.1136\/bmj.290.6471.811","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"14","key":"2552_CR13","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"DM Nathan","year":"1993","unstructured":"The Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329(14):977\u2013986. https:\/\/doi.org\/10.1056\/NEJM199309303291401","journal-title":"N Engl J Med"},{"issue":"8","key":"2552_CR14","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1007\/s00125-004-1473-9","volume":"47","author":"CS Arun","year":"2004","unstructured":"Arun CS, Pandit R, Taylor R (2004) Long-term progression of retinopathy after initiation of insulin therapy in type 2 diabetes: an observational study. Diabetologia 47(8):1380\u20131384. https:\/\/doi.org\/10.1007\/s00125-004-1473-9","journal-title":"Diabetologia"},{"issue":"2","key":"2552_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2337\/diacare.25.2.381","volume":"25","author":"M Henricsson","year":"2002","unstructured":"Henricsson M, Berntorp K, Fernlund P, Sundkvist G (2002) Progression of retinopathy in insulin-treated type 2 diabetic patients. Diabetes Care 25(2):381\u2013385. https:\/\/doi.org\/10.2337\/diacare.25.2.381","journal-title":"Diabetes Care"},{"issue":"3","key":"2552_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.diabres.2013.03.018","volume":"100","author":"A Shurter","year":"2013","unstructured":"Shurter A, Genter P, Ouyang D, Ipp E (2013) Euglycemic progression: worsening of diabetic retinopathy in poorly controlled type 2 diabetes in minorities. Diabetes Res Clin Pract 100(3):362\u2013367. https:\/\/doi.org\/10.1016\/j.diabres.2013.03.018","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"2552_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2337\/diacare.24.4.631","volume":"24","author":"J Rosenstock","year":"2001","unstructured":"Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24(4):631\u2013636. https:\/\/doi.org\/10.2337\/diacare.24.4.631","journal-title":"Diabetes Care"},{"issue":"7","key":"2552_CR18","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/bjo.82.7.725","volume":"82","author":"E Chantelau","year":"1998","unstructured":"Chantelau E (1998) Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 82(7):725\u2013730. https:\/\/doi.org\/10.1136\/bjo.82.7.725","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"2552_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabet.2017.10.014","volume":"44","author":"S Feldman-Billard","year":"2018","unstructured":"Feldman-Billard S, Larger \u00c9, Massin P (2018) Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes. Diabetes Metab 44(1):4\u201314. https:\/\/doi.org\/10.1016\/j.diabet.2017.10.014","journal-title":"Diabetes Metab"},{"issue":"3","key":"2552_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dom.13538","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain SC, Klufas MA, Ho A, Matthews DR (2019) Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review. Diabetes Obes Metab 21(3):454\u2013466. https:\/\/doi.org\/10.1111\/dom.13538","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"2552_CR21","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2337\/dc22-2521","volume":"46","author":"R Sim\u00f3","year":"2023","unstructured":"Sim\u00f3 R, Franch-Nadal J, Vlacho B, Real J, Amado E, Flores J et al (2023) Rapid reduction of HbA1c and early worsening of diabetic retinopathy: A real-world population-based study in subjects with type 2 diabetes. Diabetes Care 46(9):1633\u20131639. https:\/\/doi.org\/10.2337\/dc22-2521","journal-title":"Diabetes Care"},{"issue":"1","key":"2552_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jamaophthalmol.2024.5219","volume":"143","author":"H Tesfaye","year":"2025","unstructured":"Tesfaye H, Paik JM, Roh M, Htoo PT, Zakoul H, Schmedt N et al (2025) Empagliflozin and the risk of retinopathy in patients with type 2 diabetes. JAMA Ophthalmol 143(1):62\u201371. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.5219","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"2552_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2337\/dc13-2251","volume":"37","author":"LP Aiello","year":"2014","unstructured":"Aiello LP, DCCT\/EDIC Research Group (2014) Diabetic retinopathy and other ocular findings in the diabetes control and complications trial\/epidemiology of diabetes interventions and complications study. Diabetes Care 37(1):17\u201323. https:\/\/doi.org\/10.2337\/dc13-2251","journal-title":"Diabetes Care"},{"issue":"5","key":"2552_CR24","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2337\/dc18-2308","volume":"42","author":"DP Hainsworth","year":"2019","unstructured":"Hainsworth DP, Bebu I, Aiello LP et al (2019) Risk factors for retinopathy in type 1 diabetes: the DCCT\/EDIC study. Diabetes Care 42(5):875\u2013882. https:\/\/doi.org\/10.2337\/dc18-2308","journal-title":"Diabetes Care"},{"issue":"2","key":"2552_CR25","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2337\/db14-0930","volume":"64","author":"JM Lachin","year":"2015","unstructured":"Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group, Lachin JM, White NH, Hainsworth DP, Sun W, Cleary PA, Nathan DM (2015) Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT\/EDIC. Diabetes 64(2):631\u2013642. https:\/\/doi.org\/10.2337\/db14-0930","journal-title":"Diabetes"},{"issue":"2","key":"2552_CR26","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s001250051594","volume":"44","author":"IM Stratton","year":"2001","unstructured":"Stratton IM, Kohner EM, Aldington SJ et al (2001) UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44(2):156\u2013163. https:\/\/doi.org\/10.1007\/s001250051594","journal-title":"Diabetologia"},{"issue":"3","key":"2552_CR27","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1046\/j.1464-5491.2001.00458.x","volume":"18","author":"EM Kohner","year":"2001","unstructured":"Kohner EM, Stratton IM, Aldington SJ, Holman RR, Matthews DR, UK Prospective Diabetes Study (UKPDS) Group (2001) Relationship between the severity of retinopathy and progression to photocoagulation in patients with type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 18(3):178\u2013184. https:\/\/doi.org\/10.1046\/j.1464-5491.2001.00458.x","journal-title":"Diabet Med"},{"issue":"5","key":"2552_CR28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2337\/dc15-1897","volume":"39","author":"N Azad","year":"2016","unstructured":"Azad N, Bahn GD, Emanuele NV et al (2016) Association of blood glucose control and lipids with diabetic retinopathy in the veterans affairs diabetes trial (VADT). Diabetes Care 39(5):816\u2013822. https:\/\/doi.org\/10.2337\/dc15-1897","journal-title":"Diabetes Care"},{"issue":"3","key":"2552_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1001288","volume":"363","author":"EY Chew","year":"2010","unstructured":"ACCORD Study Group, ACCORD Eye Study Group, Chew EY, Ambrosius WT, Davis MD et al (2010) Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363(3):233\u2013244. https:\/\/doi.org\/10.1056\/NEJMoa1001288","journal-title":"N Engl J Med"},{"issue":"12","key":"2552_CR30","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","volume":"121","author":"EY Chew","year":"2014","unstructured":"Chew EY, Davis MD, Danis RP, Action to Control Cardiovascular Risk in Diabetes Eye Study Research Group (2014) The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the action to control cardiovascular risk in diabetes (ACCORD) eye study. Ophthalmology 121(12):2443\u20132451. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.019","journal-title":"Ophthalmology"},{"issue":"2","key":"2552_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/(SICI)1096-9136(199702)14:2<123::AID-DIA306>3.0.CO;2-U","volume":"14","author":"M Henricsson","year":"1997","unstructured":"Henricsson M, Nilsson A, Janzon L, Groop L (1997) The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 14(2):123\u2013131.","journal-title":"Diabet Med"},{"issue":"6","key":"2552_CR32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S2213-8587(17)30104-3","volume":"2","author":"S Zoungas","year":"2012","unstructured":"Zoungas S, Arima H, Gerstein HC et al (2012) Collaborators on trials of Lowering glucose (CONTROL) group. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: A meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2(6):434\u2013444. https:\/\/doi.org\/10.1016\/S2213-8587(17)30104-3","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2552_CR33","doi-asserted-by":"publisher","first-page":"CD009122","DOI":"10.1002\/14651858.CD009122.pub2","volume":"2014","author":"B Fullerton","year":"2014","unstructured":"Fullerton B, Jeitler K, Seitz M, Horvath K, Berghold A, Siebenhofer A (2014) Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev 2014(2):CD009122. https:\/\/doi.org\/10.1002\/14651858.CD009122.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2552_CR34","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.ajo.2015.07.024","volume":"160","author":"SA Virk","year":"2015","unstructured":"Virk SA, Donaghue KC, Wong TY, Craig ME (2015) Interventions for diabetic retinopathy in type 1 diabetes: systematic review and meta-analysis. Am J Ophthalmol 160(5):1055\u20131064e4. https:\/\/doi.org\/10.1016\/j.ajo.2015.07.024","journal-title":"Am J Ophthalmol"},{"issue":"Suppl 1","key":"2552_CR35","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc22-S009","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee (2022) Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1):S125\u2013S143. https:\/\/doi.org\/10.2337\/dc22-S009","journal-title":"Diabetes Care"},{"issue":"3 Suppl","key":"2552_CR36","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.amjmed.2009.12.008","volume":"123","author":"RA DeFronzo","year":"2010","unstructured":"DeFronzo RA (2010) Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going. Am J Med 123(3 Suppl):S38\u2013S48. https:\/\/doi.org\/10.1016\/j.amjmed.2009.12.008","journal-title":"Am J Med"},{"issue":"9","key":"2552_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","volume":"18","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, Zong Y, Ma Y et al (2024) Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther 18(9):234. https:\/\/doi.org\/10.1038\/s41392-024-01931-z","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"2552_CR38","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ (2018) Mechanisms of action and therapeutic application of Glucagon-like Peptide-1. Cell Metab 27(4):740\u2013756. https:\/\/doi.org\/10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"issue":"3","key":"2552_CR39","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/13543784.2025.2473062","volume":"34","author":"N Alkhouri","year":"2025","unstructured":"Alkhouri N, Charlton M, Gray M, Noureddin M (2025) The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists. Expert Opin Investig Drugs 34(3):169\u2013195. https:\/\/doi.org\/10.1080\/13543784.2025.2473062","journal-title":"Expert Opin Investig Drugs"},{"issue":"20","key":"2552_CR40","doi-asserted-by":"publisher","first-page":"12428","DOI":"10.3390\/ijms232012428","volume":"23","author":"A Puddu","year":"2022","unstructured":"Puddu A, Maggi D (2022) Anti-Inflammatory effects of GLP-1R activation in the retina. Int J Mol Sci 23(20):12428. https:\/\/doi.org\/10.3390\/ijms232012428","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2552_CR41","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.2337\/db16-1364","volume":"66","author":"R Sim\u00f3","year":"2017","unstructured":"Sim\u00f3 R, Hern\u00e1ndez C (2017) GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe?? Diabetes 66(6):1453\u20131460. https:\/\/doi.org\/10.2337\/db16-1364","journal-title":"Diabetes"},{"issue":"10193","key":"2552_CR42","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) REWIND investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"issue":"4","key":"2552_CR43","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) LEADER steering committee; LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"issue":"11","key":"2552_CR44","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1097\/IAE.0000000000004252","volume":"44","author":"R Rajagopal","year":"2024","unstructured":"Rajagopal R, McGill JB (2024) Novel agents in the management of diabetes and risk of worsening diabetic retinopathy. Retina 44(11):1851\u20131859. https:\/\/doi.org\/10.1097\/IAE.0000000000004252","journal-title":"Retina"},{"issue":"1","key":"2552_CR45","doi-asserted-by":"publisher","first-page":"e000475","DOI":"10.1136\/bmjdrc-2017-000475","volume":"6","author":"GP Fadini","year":"2018","unstructured":"Fadini GP, Sarangdhar M, Avogaro A (2018) Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA adverse event reporting system. BMJ Open Diabetes Res Care 6(1):e000475. https:\/\/doi.org\/10.1136\/bmjdrc-2017-000475","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"10","key":"2552_CR46","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00592-017-1031-9","volume":"54","author":"I Dicembrini","year":"2017","unstructured":"Dicembrini I, Nreu B, Scatena A et al (2017) Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 54(10):933\u2013941. https:\/\/doi.org\/10.1007\/s00592-017-1031-9","journal-title":"Acta Diabetol"},{"issue":"1","key":"2552_CR47","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2337\/db15-0443","volume":"65","author":"C Hern\u00e1ndez","year":"2016","unstructured":"Hern\u00e1ndez C, Bogdanov P, Corraliza L et al (2016) Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 65(1):172\u2013187. https:\/\/doi.org\/10.2337\/db15-0443Epub 2015 Sep 17","journal-title":"Diabetes"},{"issue":"4","key":"2552_CR48","doi-asserted-by":"publisher","first-page":"dgz069","DOI":"10.1210\/clinem\/dgz069","volume":"105","author":"B Gaborit","year":"2020","unstructured":"Gaborit B, Julla JB, Besbes S et al (2020) Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the AngioSafe type 2 diabetes study. J Clin Endocrinol Metab 105(4):dgz069. https:\/\/doi.org\/10.1210\/clinem\/dgz069","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2552_CR49","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 45(11):2753\u20132786. https:\/\/doi.org\/10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"2552_CR50","doi-asserted-by":"publisher","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D et al (2024) Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ 384:e076410. https:\/\/doi.org\/10.1136\/bmj-2023-076410PMID: 38286487; PMCID: PMC10823535","journal-title":"BMJ"},{"issue":"2","key":"2552_CR51","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U et al (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 327(2):138\u2013150. https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"JAMA"},{"issue":"1","key":"2552_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26502\/aimr.0189","volume":"8","author":"L Pillarisetti","year":"2025","unstructured":"Pillarisetti L, Agrawal DK (2025) Semaglutide: Double-edged sword with risks and benefits. Arch Intern Med Res 8(1):1\u201313. https:\/\/doi.org\/10.26502\/aimr.0189Epub 2025 Jan 10","journal-title":"Arch Intern Med Res"},{"issue":"4","key":"2552_CR53","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.13172","volume":"20","author":"T Vilsb\u00f8ll","year":"2018","unstructured":"Vilsb\u00f8ll T, Bain SC, Leiter LA et al (2018) Semaglutide, reduction in glycated hemoglobin, and the risk of diabetic retinopathy. Diabetes Obes Metab 20(4):889\u2013897. https:\/\/doi.org\/10.1111\/dom.13172","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2552_CR54","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41433-021-01741-5","volume":"36","author":"A Sharma","year":"2022","unstructured":"Sharma A, Parachuri N, Kumar N et al (2022) Semaglutide and the risk of diabetic retinopathy\u2014current perspective. Eye (Lond) 36(1):10\u201311. https:\/\/doi.org\/10.1038\/s41433-021-01741-5","journal-title":"Eye (Lond)"},{"issue":"8","key":"2552_CR55","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/eye.2017.119","volume":"31","author":"Y Chen","year":"2017","unstructured":"Chen Y, Laybourne JP, Sandinha MT et al (2017) Does bariatric surgery prevent progression of diabetic retinopathy? Eye (Lond) 31(8):1131\u20131139. https:\/\/doi.org\/10.1038\/eye.2017.119","journal-title":"Eye (Lond)"},{"issue":"2","key":"2552_CR56","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1001\/jamaophthalmol.2020.5892","volume":"139","author":"H \u00c5kerblom","year":"2021","unstructured":"\u00c5kerblom H, Franz\u00e9n S, Zhou C et al (2021) Association of gastric bypass surgery with risk of developing diabetic retinopathy among patients with obesity and type 2 diabetes in sweden: an observational study. JAMA Ophthalmol 139(2):200\u2013205. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.5892","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"2552_CR57","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I et al (2018) Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6(4):275\u2013286. https:\/\/doi.org\/10.1016\/S2213-8587(18)30024-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2552_CR58","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381(9):841\u2013851. https:\/\/doi.org\/10.1056\/NEJMoa1901118","journal-title":"N Engl J Med"},{"key":"2552_CR59","doi-asserted-by":"publisher","first-page":"100168","DOI":"10.1016\/j.endmts.2024.100168","volume":"15","author":"H Stevens","year":"2024","unstructured":"Stevens H, de la Paz M, Cooper B, Bhattacharya R (2024) Long-term use of semaglutide and risk of diabetic retinopathy progression. Endocr Metab Sci 15:100168. https:\/\/doi.org\/10.1016\/j.endmts.2024.100168","journal-title":"Endocr Metab Sci"},{"issue":"3","key":"2552_CR60","doi-asserted-by":"publisher","first-page":"394","DOI":"10.4093\/dmj.2022.0221","volume":"47","author":"TY Lin","year":"2023","unstructured":"Lin TY, Kang EY, Shao SC et al (2023) Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Diabetes Metab J 47(3):394\u2013404. https:\/\/doi.org\/10.4093\/dmj.2022.0221","journal-title":"Diabetes Metab J"},{"issue":"7","key":"2552_CR61","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00125-024-06132-5","volume":"67","author":"A Eleftheriadou","year":"2024","unstructured":"Eleftheriadou A, Riley D, Zhao SS et al (2024) Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Diabetologia 67(7):1271\u20131282. https:\/\/doi.org\/10.1007\/s00125-024-06132-5","journal-title":"Diabetologia"},{"issue":"9662","key":"2552_CR62","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","volume":"373","author":"A Garber","year":"2009","unstructured":"Garber A, Henry R, Ratner R, LEAD-3 (Mono) Study Group et al (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373(9662):473\u2013481","journal-title":"Lancet"},{"key":"2552_CR63","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fendo.2014.00044","volume":"5","author":"N Lois","year":"2014","unstructured":"Lois N, McCarter RV, O\u2019Neill C, Medina RJ, Stitt AW (2014) Endothelial progenitor cells in diabetic retinopathy. Front Endocrinol (Lausanne) 5:44. https:\/\/doi.org\/10.3389\/fendo.2014.00044","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2552_CR64","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s13300-015-0127-x","volume":"6","author":"A Uccellatore","year":"2015","unstructured":"Uccellatore A, Genovese S, Dicembrini I, Mannucci E, Ceriello A (2015) Comparison review of Short-Acting and Long-Acting Glucagon-like Peptide-1 receptor agonists. Diabetes Ther 6(3):239\u2013256. https:\/\/doi.org\/10.1007\/s13300-015-0127-x","journal-title":"Diabetes Ther"},{"key":"2552_CR65","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","volume":"384","author":"ST Povedano","year":"2014","unstructured":"Povedano ST, Dungan KM, Forst T et al (2014) Once-weekly dulaglutide versus once-daily liraglutide in metformin- treated patients with type 2 diabetes (AWARD-6): randomised, open-label, phase 3, non-inferiority trial. Lancet 384:1349\u20131357","journal-title":"Lancet"},{"issue":"2","key":"2552_CR66","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G et al (2018) Efficacy and safety of Once-Weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-Week, Open-Label, randomized clinical trial. Diabetes Care 41(2):258\u2013266. https:\/\/doi.org\/10.2337\/dc17-0417","journal-title":"Diabetes Care"},{"issue":"13","key":"2552_CR67","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377(13):1228\u20131239. https:\/\/doi.org\/10.1056\/NEJMoa1612917","journal-title":"N Engl J Med"},{"issue":"3","key":"2552_CR68","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.2040-1124.2011.00128.x","volume":"2","author":"K Kaku","year":"2011","unstructured":"Kaku K, Rasmussen MF, Nishida T, Seino Y (2011) Fifty-two-week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon-like peptide-1 analog liraglutide vs Glibenclamide in patients with type 2 diabetes. J Diabetes Investig 2(3):249\u2013256. https:\/\/doi.org\/10.1111\/j.2040-1124.2011.00128.x","journal-title":"J Diabetes Investig"},{"issue":"3","key":"2552_CR69","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jdiacomp.2014.01.012","volume":"28","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Hanefeld M, Shamanna P, Min KW, Boka G, Miossec P et al (2014) Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without Metformin (GetGoal-S). J Diabetes Complications 28(3):386\u2013392. https:\/\/doi.org\/10.1016\/j.jdiacomp.2014.01.012","journal-title":"J Diabetes Complications"},{"issue":"Suppl 1","key":"2552_CR70","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/jdi.12490","volume":"7","author":"Y Seino","year":"2016","unstructured":"Seino Y, Kuwata H, Yabe D (2016) Incretin-based drugs for type 2 diabetes: focus on East Asian perspectives. J Diabetes Investig 7(Suppl 1):102\u2013109. https:\/\/doi.org\/10.1111\/jdi.12490","journal-title":"J Diabetes Investig"},{"issue":"2","key":"2552_CR71","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2337\/dc19-1065","volume":"43","author":"MA Bethel","year":"2020","unstructured":"Bethel MA, Mentz RJ, Merrill P et al (2020) Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial. Diabetes Care 43(2):446\u2013452. https:\/\/doi.org\/10.2337\/dc19-1065","journal-title":"Diabetes Care"},{"issue":"23","key":"2552_CR72","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373(23):2247\u20132257. https:\/\/doi.org\/10.1056\/NEJMoa1509225","journal-title":"N Engl J Med"},{"key":"2552_CR73","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1016\/j.diabres.2011.08.017","volume":"94","author":"L Varadhan","year":"2011","unstructured":"Varadhan L, Humphreys T, Hariman C, Walker AB, Varughese GI (2011) GLP-1 agonist treatment: implications for diabetic retinopathy screening. Diabetes Res Clin Pract 94:e68\u2013e71. https:\/\/doi.org\/10.1016\/j.diabres.2011.08.017","journal-title":"Diabetes Res Clin Pract"},{"key":"2552_CR74","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.diabres.2013.12.041","volume":"103","author":"L Varadhan","year":"2014","unstructured":"Varadhan L, Humphreys T, Walker AB, Varughese GI (2014) The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy. Diabetes Res Clin Pract 103:e37\u2013e39. https:\/\/doi.org\/10.1016\/j.diabres.2013.12.041","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2552_CR75","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2337\/dc20-1815","volume":"44","author":"MA Bethel","year":"2021","unstructured":"Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC (2021) HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: A meta-analysis and meta-regression. Diabetes Care 44(1):290\u2013296. https:\/\/doi.org\/10.2337\/dc20-1815","journal-title":"Diabetes Care"},{"issue":"8","key":"2552_CR76","doi-asserted-by":"publisher","first-page":"108255","DOI":"10.1016\/j.jdiacomp.2022.108255","volume":"36","author":"Y Yoshida","year":"2022","unstructured":"Yoshida Y, Joshi P, Barri S et al (2022) Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis. J Diabetes Complications 36(8):108255. https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108255","journal-title":"J Diabetes Complications"},{"key":"2552_CR77","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","volume":"265","author":"KM Wai","year":"2024","unstructured":"Wai KM, Mishra K, Koo E et al (2024) Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study. Am J Ophthalmol 265:39\u201347. https:\/\/doi.org\/10.1016\/j.ajo.2024.04.010","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"2552_CR78","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.2337\/dc17-2280","volume":"41","author":"A Douros","year":"2018","unstructured":"Douros A, Filion KB, Yin H et al (2018) Glucagon-Like peptide 1 receptor agonists and the risk of incident diabetic retinopathy. Diabetes Care 41(11):2330\u20132338. https:\/\/doi.org\/10.2337\/dc17-2280","journal-title":"Diabetes Care"},{"issue":"1","key":"2552_CR79","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12916-023-02753-6","volume":"21","author":"D Zheng","year":"2023","unstructured":"Zheng D, Li N, Hou R et al (2023) Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. BMC Med 21(1):40. https:\/\/doi.org\/10.1186\/s12916-023-02753-6","journal-title":"BMC Med"},{"issue":"3","key":"2552_CR80","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00417-023-06236-5","volume":"262","author":"DP Ntentakis","year":"2024","unstructured":"Ntentakis DP, Correa VSMC, Ntentaki AM et al (2024) Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review. Graefes Arch Clin Exp Ophthalmol 262(3):717\u2013752. https:\/\/doi.org\/10.1007\/s00417-023-06236-5","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"2552_CR81","doi-asserted-by":"publisher","first-page":"100547","DOI":"10.1016\/j.xops.2024.100547","volume":"4","author":"JH Joo","year":"2024","unstructured":"Joo JH, Sharma N, Shaia J et al (2024) The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center. Ophthalmol Sci 4(6):100547. https:\/\/doi.org\/10.1016\/j.xops.2024.100547","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"2552_CR82","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/XCE.0000000000000209","volume":"10","author":"S Lahoti","year":"2020","unstructured":"Lahoti S, Nashawi M, Sheikh O et al (2020) Sodium-glucose co-transporter 2 inhibitors and diabetic retinopathy: insights into preservation of sight and looking beyond. Cardiovasc Endocrinol Metab 10(1):3\u201313. https:\/\/doi.org\/10.1097\/XCE.0000000000000209","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"2552_CR83","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J (2019) The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne) 10:155. https:\/\/doi.org\/10.3389\/fendo.2019.00155","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2552_CR84","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","volume":"142","author":"JT Hathaway","year":"2024","unstructured":"Hathaway JT, Shah MP, Hathaway DB et al (2024) Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol 142(8):732\u2013739. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2296","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"2552_CR85","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamaophthalmol.2024.4515","volume":"142","author":"JB Lusk","year":"2024","unstructured":"Lusk JB, Mac Grory B, Li F (2024) Considerations regarding association of semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol 142(12):1173\u20131174. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.4515","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"2552_CR86","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1177\/19322968241268050","volume":"18","author":"DC Klonoff","year":"2024","unstructured":"Klonoff DC, Hui G, Gombar S (2024) Real-word evidence assessment of the risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. J Diabetes Sci Technol 18(6):1517\u20131518. https:\/\/doi.org\/10.1177\/19322968241268050","journal-title":"J Diabetes Sci Technol"},{"issue":"12","key":"2552_CR87","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamaophthalmol.2024.4518","volume":"142","author":"JS Xie","year":"2024","unstructured":"Xie JS, Trobe J, Margolin E (2024) Considerations regarding association of semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol 142(12):1174. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.4518","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"2552_CR88","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","volume":"10","author":"J Grauslund","year":"2024","unstructured":"Grauslund J, Taha AA, Molander LD et al (2024) Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous 10(1):97. https:\/\/doi.org\/10.1186\/s40942-024-00620-x","journal-title":"Int J Retina Vitreous"},{"issue":"4","key":"2552_CR89","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1001\/jamaophthalmol.2024.6555","volume":"143","author":"CX Cai","year":"2025","unstructured":"Cai CX, Hribar M, Baxter S et al (2025) Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol 143(4):304\u2013314. https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.6555","journal-title":"JAMA Ophthalmol"},{"key":"2552_CR90","doi-asserted-by":"publisher","DOI":"10.1111\/aos.17473","author":"A Amini","year":"2025","unstructured":"Amini A, Hamann S, Larsen M (2025) Semaglutide and non-arteritic Ischaemin optic neuropathy: review and interpretation of reported association. Acta Ophthalmol. https:\/\/doi.org\/10.1111\/aos.17473Online ahead of print","journal-title":"Acta Ophthalmol"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02552-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-025-02552-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02552-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:41:20Z","timestamp":1761907280000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-025-02552-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":90,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["2552"],"URL":"https:\/\/doi.org\/10.1007\/s00592-025-02552-w","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}